Double Bond Pharma signs agreement for distribution of Helixor products
Double Bond Pharmaceutical (DBP) and Helixor Heilmittel GmbH have today signed an agreement for distribution of Helixor products in Sweden. The distribution will be held through Drugsson AB. Helixor products are used as integrative cancer therapy, which means that they are given to the patient to decrease severe side effects from their current medication and substantially increase quality of life. Helixor products are available for integrative treatment of different types of cancers, both common and rare cancers, including breast cancer, colorectal cancer, lung cancer and brain cancer.